Quince Therapeutics, Inc., was incorporated in Delaware on June 20, 2012. The company is a clinical-stage biopharmaceutical company that has pioneered a novel disease-improving treatment for what is considered a key root cause of Alzheimer's and degenerative diseases. The company's approach is based on the groundbreaking discovery of gingival porphyromonas gingivalis or P. gingivalis and its secreted toxic virulence factor proteases called gingipains in the brains of more than 100 Alzheimer's patients observed through multiple studies to date. In addition, the company has observed in animal models that Pseudomonas gingivalis infection leads to Alzheimer's pathology, and these effects have been successfully treated with gum pain inhibitors in preclinical studies. The company's proprietary lead drug candidate COR388 is an orally administered, brain-penetrating small molecule gingival pain inhibitor. COR388 has been well tolerated with no associated safety signals in the Phase 1 and Phase 1 b clinical trials conducted to date, which enrolled a total of 67 subjects, including nine patients with mild to moderate Alzheimer's disease.